Form 10-12B
Please substantiate that you have a “best-in-class” cost structure versus your peers. Also clarify whether this is aspirational and discuss the steps you are taking to achieve this goal and the factors you consider in benchmarking your performance.
to the Staff’s comment, the Company has updated the disclosure on page 135 of the Amended Information Statement to further describe how Corteva’s cost structure is expected to be benchmarked against its peers. The Company has also updated the disclosure on pages 7, 8, 9, 100, 101, 135, 138, 139 and 140 of the Amended Information Statement to clarify the aspirational nature of its target cost structure and to further outline the steps being taken to achieve this aspirational goal.Read in the reply
Please include diagrams illustrating: the existing DowDuPont corporate structure; the corporate structure immediately following the separation/internal reorganization; and the distribution.
to the Staff’s comment, we have provided illustrative diagrams on pages 4 and 5 of the Amended Information Statement.Read in the reply
Reasons for the Separation and Distribution,
You state here reasons for the separation include, among other reasons, creating a focused business, tailored growth strategies, sharper focus on core business, and the ability of management to implement strategies tailored to each company’s specific business characteristics.Rest of the question
Please describe the most significant differences in strategy, operating priorities, and business focus between Corteva and DowDuPont prior to the separation.
The Company respectfully acknowledges the Staff’s comment. The existing DowDuPont operating segment structure aligns closely with the three businesses that are intended to ultimately operate as three future independent, publicly traded companies (Corteva,Read in the reply
Dow and New DuPont) following the separations and distributions of Dow and Corteva. After its separation and distribution, Corteva is expected to hold the assets and liabilities associated with DowDuPont’s agriculture business.Rest of the answer
Given this alignment, the Company expects that its initial strategies, operating priorities and business focus after the separations and distributions will generally mirror the strategies, operating priorities and business focus of the DowDuPont agriculture segment. However, as disclosed in the section entitled “Our Strategy” on pages 138 to 140 of the Amended Information Statement, the Company does expect that its strategy, operation priorities and business focus will be differentiated from the existing strategy by an increased emphasis on maintaining a more streamlined, efficient and focused operating structure, which the Company expects to achieve by, among other things, integrating its operations, continuing to drive operating efficiencies, realizing significant cost synergies and continually improving its cost structure. The Company also continues to believe that by operating as a pure play agriculture business, it can be more sharply focused on the needs of farmers and instill a culture that best supports its unique strategy. The Company has revised the disclosure included under the section entitled “Our Strategy” on page 9 and pages 138 to 140 of the Amended Information Statement to clarify that a number of the strategies listed will be continuations of the existing strategies implemented by the agriculture segment of DowDuPont.
In the first bullet point on page 53, please briefly discuss Corteva’s capital allocation needs and how its capital structure will facilitate meeting these needs.
to the Staff’s comment, the Company has revised the disclosure on page 96 of the Amended Information Statement to discuss Corteva’s capital allocation needs and how its capital structure will facilitate meeting these needs.Read in the reply
We note your disclosure that certain events and circumstances in 2018 along with a reduction in cash flow projections caused a triggering event that required Historical DuPont to perform an impairment analysis of its agriculture reporting unit's goodwill and indefinite-lived intangible assets as of September 30, 2018, and that as a result, Historical DuPont recorded pre-tax (and after-tax), non-cash impairmentRest of the question
charges of about $4.5 billion for goodwill and $0.1 billion for certain indefinite-lived assets associated with its agriculture reporting unit. Please tell us the significant assumptions Historical DuPont used to determine the estimated fair value of its agriculture reporting unit during the quarter ended September 30, 2018 and more fully explain the facts and circumstances that resulted in these impairments to be recorded during this interim period.
to the Staff’s comment, the Company has revised the disclosure on page 127 of the AmendedRead in the reply
Information Statement to more fully explain the facts and circumstances that resulted in the recording of these impairments during the fiscal quarter ended September 30, 2018.
Please provide context for the Cost Synergy Program by discussing and quantifying, to the extent you are able, the potential loss of synergies and one-time costs associated with the separation.
to the Staff’s comment, the Company has revised the disclosure underRead in the reply
“Note 3” of the section entitled “Unaudited Pro Forma Combined Financial Statements” on pages 74 to 77 of the Amended Information Statement to reflect that DowDuPont has incurred certain one-time costs directly attributable to the separation and distribution of Corteva, which have been excluded from the combined pro forma statements of income in accordance with rules of Article 11 of Regulation S-X.Rest of the answer
Additionally, the Company has revised the disclosure on page 102 of the Amended Information Statement to reflect that Corteva expects to incur certain additional costs relating to the operation and integration of the Company’s historical ERP systems and the establishment of a corporate structure.
In the second paragraph of this subsection, please disclose the amount of the cost synergy commitment attributable to Historical DuPont.
to the Staff’s comment, the Company has revised the disclosure on page 102 of the Amended Information Statement to specify the total amount of the DowDuPont cost synergy commitment as well as the amount of the cost synergy commitment that will be attributable to Corteva.Read in the reply
Please substantiate your statement here and on page 132 that you have the broadest CRISPR intellectual property estate in the agricultural industry.
to the Staff’s comment, the Company has revised the disclosure included on pages 137 and 142 of the Amended Information Statement.Read in the reply
We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action.” Please disclose whether this provision applies to actions arising under the Securities Act or Exchange Act.Rest of the question
In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision, and that stockholders will not be deemed to have waived the company’s compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, also ensure that the exclusive forum provision in the governing documents states this clearly. Similarly revise the carryover risk factor on pages 49-50.
to the Staff’s comment, the Company has revised the disclosure on page 210 and included an additional risk factor on page 50 to clarify that the Company’s amended and restated by-laws will not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under federal securities laws. In addition, the Company has revised its governing documents and has filed the revised form of the Company’s amended and restated by-laws as Exhibit 3.2 to Amendment No. 3.Read in the reply
Also in this review: company letter, May 3, 2019, closing letter, 2019-05-07